Investors Encouraged to Join Class Action Against Immutep Limited for Alleged Securities Fraud
Investors Have Chance to Take Action Against Immutep Limited
Investors in Immutep Limited (NASDAQ: IMMP) have a unique opportunity to join a class action lawsuit led by The Schall Law Firm, which specializes in shareholder rights litigation. The lawsuit pertains to alleged violations of the Securities Exchange Act of 1934, specifically under §§10(b) and 20(a) and Rule 10b-5.
The class action targets investors who purchased Immutep's securities during a specific time frame from March 24, 2025, to March 12, 2026. If you find yourself in this category, you are encouraged to take action before the deadline on July 6, 2026.
Understanding the Claims
According to the complaint filed, Immutep has been accused of making false and misleading statements, particularly concerning the results from its TACTI-004 trial for the drug eftilagimod alfa (commonly referred to as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.